C4 Therapeutics (CCCC) has provided an update.
In a recent corporate shake-up, the Company has announced Dr. Fawell’s appointment to the Board while acknowledging Mr. Salter’s departure. This move, detailed in a press release, marks a significant change in the Company’s leadership structure, which could influence its strategic direction and potentially impact its stock performance in the financial markets.
Find detailed analytics on CCCC stock on TipRanks’ Stock Analysis page.
